Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7994447 | 0.98 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL7994444 | 0.98 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL7994499 | 0.94 | — | — | |
| SCHEMBL4744556 | 0.81 | KMT2A (0.33) | SMN1; SMN2 | |
| SCHEMBL466743 | 0.79 | TAAR1 (0.34) | SMN1; SMN2 | |
| SCHEMBL8125749 | 0.79 | KMT2A (0.33) | SMN1; SMN2 | |
| SCHEMBL7994426 | 0.79 | KMT2A (0.33) | SMN1; SMN2 | |
| SCHEMBL2701925 | 0.79 | — | — | |
| SCHEMBL20290520 | 0.78 | TAAR1 (0.33) | SMN1; SMN2 | |
| SCHEMBL10338316 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255121-A1 | Combination Drug for Treating Autoimmune Disease | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1815867-A1 | COMBINATION DRUG FOR TREATING AUTOIMMUNE DISEASE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-08-08 | — | — | EP | disclosed |
| EP-0979226-B1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1201661-A1 | HETEROAROMATIC RING COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-6277790-B1 | APPLYING PLANTS, SEEDS, SOILS OR ENVIRONMENT | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-21 | — | — | US | disclosed |
| US-6100260-A | ((3-(1-(2-FLUORO-BIPHENYL-4-YL)-ETHYL)-ISOXAZOL-5-YLIMINO) -MORPHOLIN-4-YL-M ETHYL)-AMINE, FOR EXAMPLE; ADMINISTERING TO TREAT AUTOIMMUNE DISEASES AND INFLAMMATION | SUMITOMO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-08 | — | — | US | disclosed |
| EP-0979226-A1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998047880-A1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255121-A1 | Combination Drug for Treating Autoimmune Disease | CAMK2D, CAMK2G, CAMK2B | SMN1; SMN2 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.